A BILL 
To require guidance on extending expiration dates for certain 
drugs, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Drug Shortages Shelf 
4
Life Extension Act’’. 
5
SEC. 2. EXTENDING EXPIRATION DATES FOR CERTAIN 
6
DRUGS. 
7
(a) IN GENERAL.—Not later than 1 year after the 
8
date of enactment of this Act, the Secretary of Health and 
9
Human Services (referred to in this section as the ‘‘Sec-
10
02:54 May 07, 2022
H7669
2 
•HR 7669 IH
retary’’) shall issue draft guidance, or revise existing guid-
1
ance, to address recommendations for sponsors of applica-
2
tions submitted under section 505 of the Federal Food, 
3
Drug, and Cosmetic Act (21 U.S.C. 355) or section 351 
4
of the Public Health Service Act (42 U.S.C. 262) regard-
5
ing— 
6
(1) the submission of stability testing data in 
7
such applications, including considerations for data 
8
requirements that could be streamlined or reduced 
9
to facilitate faster review of longer proposed expira-
10
tion dates; 
11
(2) establishing in the labeling of drugs the 
12
longest feasible expiration date scientifically sup-
13
ported by such data, taking into consideration how 
14
extended expiration dates may— 
15
(A) help prevent or mitigate drug short-
16
ages; and 
17
(B) affect product quality; and 
18
(3) the use of innovative approaches for drug 
19
and combination product stability modeling to sup-
20
port initial product expiration dates and expiration 
21
date extensions. 
22
(b) REPORT.—Not later than 2 years after the date 
23
of enactment of this Act, and again 2 years thereafter, 
24
the Secretary shall submit to the Committee on Health, 
25
02:54 May 07, 2022
H7669
3 
•HR 7669 IH
Education, Labor, and Pensions of the Senate and the 
1
Committee on Energy and Commerce of the House of 
2
Representatives a report that includes— 
3
(1) the number of drugs for which the Sec-
4
retary has requested the manufacturer make a label-
5
ing change regarding the expiration date; and 
6
(2) for each drug for which the Secretary has 
7
requested a labeling change with respect to the expi-
8
ration date, information regarding the circumstances 
9
of such request, including— 
10
(A) the name and dose of such drug; 
11
(B) the rationale for the request; 
12
(C) whether the drug, at the time of the 
13
request, was listed on the drug shortage list 
14
under section 506E of the Federal Food, Drug, 
15
and Cosmetic Act (21 U.S.C. 356e), or was at 
16
risk of shortage; 
17
(D) whether the request was made during 
18
a public health emergency declared under sec-
19
tion 319 of the Public Health Service Act (42 
20
U.S.C. 247d); and 
21
(E) whether the manufacturer made the 
22
requested change by the requested date, and for 
23
instances where the manufacturer does not 
24
make the requested change, the manufacturer’s 
25
02:54 May 07, 2022
H7669
4 
•HR 7669 IH
justification for not making the change, if the 
1
manufacturer agrees to provide such justifica-
2
tion for inclusion in the report. 
3
Æ 
02:54 May 07, 2022
H7669
